Policy Number: 1
Title: Institutional Commitment and IRB Authority
Date of Last Revision: 01/29/09; 08/19/10; 05/24/11; 06/18/12; 05/01/13; 01/12/15; 01/28/15; 05/01/16; 08/01/16, 02/14/17, 06/07/17, 08/24/17, 11/27/18

Policy:
The University of California, Irvine (UCI) commits to upholding its Assurance and to registering its boards with the Office for Human Research Protections (OHRP). UCI supports review by one Institutional Review Board for multi-site clinical trials and collaborative research (single IRB review or sIRB).


B. Safeguarding the rights and welfare of human participants in research and other research activities is a general Institutional policy delegated by the Chancellor through the Vice Chancellor for Research. The Vice Chancellor for Research is the Institutional Official. It is his responsibility to exercise appropriate administrative oversight to assure that UCI’s policies and procedures designed for protecting the rights and welfare of human participants are effectively applied in compliance with its Assurance.

C. Human subjects research that takes place at UCI Campus, UCI Medical Center, the UCI Family Health Centers in Anaheim and Santa Ana and the UCI Women’s Health Care Center and Pacific Breast Care Center in Costa Mesa and UCI Health Community Cancer Network – Newport Associates are subject to the Assurance and this policy. Collectively these sites will hereafter be referred to as UCI.

D. UCI’s faculty, staff, and students, which comprise its schools, departments, divisions, institutes and facilities, are subject to the Assurance and this policy. This includes any research for which an Assurance or another formal agreement (e.g., MOU) identifies UCI’s Institutional Review Board (IRB) as the IRB of record.

E. UCI agrees to uphold the ethical principles of the [Belmont Report](http://www.bioethics.ucsf.edu/belmont_report). UCI will apply DHHS regulations (45 CFR 46, including all Subparts) to all federally-funded proposed research involving human participants. Commensurate protections are in place for all other human subject research conducted at or under the jurisdiction of UCI.

F. The ethical principles set forth in the [Belmont Report](http://www.bioethics.ucsf.edu/belmont_report) are:
   1. Respect for Persons: Recognition of the personal dignity and autonomy of individuals and special protection of those persons with diminished autonomy;
   2. Beneficence: Obligation to protect persons from harm by maximizing anticipated benefits and minimizing possible risk of harm; and

G. UCI agrees to apply additional regulations such as, the U.S. Food and Drug Administration Human Subject Regulations (21 CFR 50, 56, 312 and 812) and the Health Insurance Portability and Accountability Act of 1996 (HIPAA), when applicable, to research involving human participants.

H. Clinical trials should be conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with good clinical practices and the applicable regulatory requirements.
I. UCI must renew its FWA every 5 years, even if no changes have occurred, in order to maintain an active FWA.
J. The FWA must be updated within 90 days should a change to the name of the institution, the Human Protections Administrator or Institutional Official be made.
K. Failure to renew or update an FWA appropriately may result in restriction, suspension, or termination of OHRP's approval of the Institution's FWA.

II. IRB Registration
A. UCI IRBs are registered with the Department of Health and Human Services (HHS) as HHS regulations at 45 CFR part 46, subpart E, require all IRBs to register if they will review human subjects research conducted or supported by HHS and are to be designated under an assurance of compliance approved for Federalwide use by OHRP.
B. For IRBs that review protocols regulated by both OHRP and the Food and Drug Administration (FDA), the institution must provide the approximate number of active protocols involving FDA-regulated products and a description of the types of FDA-regulated products (such as biological products, color additives, food additives, human drugs, or medical devices) involved in the protocols that the IRB reviews.
C. UCI's IRB Organization Number is IORG 0000236. The individual IRB registration numbers are:
   1. IRB A: 0000393
   2. IRB B: 0000394
   3. IRB C: 0000395
   4. IRB E: 00008624
   5. IRB WB: 00011147
E. IRB registration must be updated within 90 days after changes occur regarding the contact person who provided the IRB registration information and/or the IRB chairperson.
F. IRB Registration is effective for three years.

III. Structure of the Human Research Protections Unit
A. The UCI Office of Research Administration (ORA) is an administrative unit of the Office of Research. Research Protections (RP) and Sponsored Projects are divisions of OR. Human Research Protections (HRP) is a unit within Research Protections. HRP facilitates and promotes the ethical involvement of human subjects in research by providing administrative support to the IRBs, and consultative services to Investigators and their research staff. The UCI HRP staff facilitates the IRB review and approval of human subjects research in accordance with applicable federal and state regulations, and UC/UCI policies and procedures.
B. The Executive Director of RP has operational and HRP personnel management responsibilities. The Executive Director reports to the Associate Vice Chancellor for Research Administration. The Associate Director of RP and Assistant Director of HRP are part of the management team that supports the operational goals of the unit.

IV. Structure of the Institutional Review Board
A. The IRB Committees are official University Regulatory Committees. The IRB Committees serve UCI as a whole, rather than a particular school or department, and any institution for which UCI’s IRB is designated as the IRB of record in an Assurance filed with OHRP with a corresponding MOU.
B. UCI’s Assurance presently designates five (5) OHRP-registered IRB Committees. Designation of additional IRB Committees under the Assurance requires prior notification of and approval by OHRP.
   1. Three Committees review biomedical research studies that are designed primarily to increase the scientific base of information about normal or abnormal physiology and development, and studies intended to evaluate the safety, efficacy, and usefulness of drugs, biologics, devices, medical products, procedures or interventions.
   2. One Committee reviews social and behavioral sciences studies that are designed primarily to contribute to behavioral, educational, psychological, and social science knowledge.
   3. One Committee primarily reviews matters of alleged non-compliance related to human subject research conducted by a UC Irvine personnel. This committee may also review unanticipated problem reports that involve matters of potential non-compliance and transactional items when needed to support ongoing research.

V. Responsibilities of the IRB to Provide Oversight in accordance with the Federalwide Assurance
A. Approval by the IRB is required prior to the initiation of all human subjects research.
B. Except for research exempted or waived in accordance with 45 CFR 46.101(b) or 45 CFR 101(i), all federally human subjects research will be reviewed, prospectively approved, and, subject to continuing oversight and review at least annually by the IRB.
C. The IRB has the authority to:
   1. Approve, require modifications in (to secure approval), or disapprove all research activities covered by this policy.
   2. Require that information given to subjects as part of informed consent is in accordance with 45 CFR 46.116 and 21 CFR 50.25. The IRB may require that information, in addition to that specifically mentioned in 45 CFR 46.116, be given to the subjects when the information would meaningfully add to the protection of the rights and welfare of subjects.
   3. Require documentation of informed consent or waive documentation in accordance with 45 CFR 46.117 and 21 CFR 50.27.
   4. Grant permission for the use of surrogate consent, in accordance with California Health and Safety Code 24178.
   5. Observe or have a third party observe the consent process and the research.
   6. Suspend, place restrictions on, or terminate approval of research activities that are not being conducted in accordance with applicable federal regulations, state statutes, and/or UC/UCI policies and procedures, or that has been associated with unanticipated problems involving risk to subjects or others.
D. Federally funded human subject research that qualifies as Exempt research in accordance with 45 CFR 46.101(b)(1-6), will be reviewed by an experienced HRP staff member or IRB Chair to confirm exempt status and registered for five years. Exempt research activities are subject to the same subject protections and ethical standards as outlined in The Belmont Report. All exempt research is subject to applicable UCI and UCI IRB policies and procedures.
E. Research reviewed and approved by the IRB may be subject to review and disapproval by officials of UCI, or any institution for which the UCI IRB is designated as the IRB of record in accordance with an Assurance or a signed MOU or IRB Authorization Agreement with the UCI. However, if the UCI IRB does not grant IRB approval or suspends or terminates IRB approval, these decisions may not be overturned anyone at a higher level.
VI. **Single IRB Review of Multi-Site Clinical Trials and Cooperative Research**

A. UCI supports the use of a single Institutional Review Board (sIRB) for multi-site research to enhance and streamline the IRB review process. sIRB eliminates duplicative IRB review thereby minimizing unnecessary administrative burdens and systemic inefficiencies while assuring human subjects protections. NOTE: Other institutional regulatory requirements such as Conflict of Interest, Radiation Safety, Institutional Biosafety must reviewed and approved at UCI.

B. UCI IRB can serve as the IRB of Record for an external site engaged in research as well as cede IRB review to a non-UCI IRB.

C. When the UCI IRB serves as the IRB of Record it is accepting the responsibility of oversight of the conduct of the research for a particular study site.

D. The terms and responsibilities of the IRB of record, the ceding Institution are documented in an IRB Authorization Agreement for a single protocol or a Memorandum of Understanding (MOU) or IRB Master Agreement for multiple research cooperative agreement.

E. UCI IRB currently has several reciprocal Master Agreements whereby any institution signed on the agreement may serve as the IRB of Record for example:  
   1. **UCI IRB Reliance** – an MOU among the other 10 UC campuses and one UC-managed Laboratories that allows one UC IRB to rely on another UC IRB for review and approval of human subjects research protocols that are:  
      a) Eligible for exempt registration, expedited review (i.e., research involving no more than minimal risk to the subjects) and protocols involving greater than minimal risk,  
      b) Will be conducted concurrently at one or more UC location, or  
      c) Involves personally identifiable data or samples from one or more UC location for which investigators at another UC location will be conducting analyses.  
      d) The MOU, effective March 21, 2006, is periodically reviewed to determine whether improvements or amendments to the MOU are needed.  
   2. **Children’s Hospital Orange County (CHOC), MemorialCare Health System (MHS) and UCI (aka CMU)** have signed a MOU that allows one IRB to rely upon another for review and approval of multi-center adult and pediatric research studies.  
   3. **SMART IRB** - the “Streamlined, Multisite, Accelerated Resources for Trials” IRB Reliance platform supported by the National Center for Advancing Translational Sciences (NCATS) to facilitate multi-site clinical trials.

F. UCI has also entered into MOUs where a non-UCI IRB is designated as the IRB of Record for example:  
   1. **National Cancer Institute Central IRB (CIRB)** for review and oversight of NCI multi-center, adult cooperative oncology studies.
   2. **StrokeNet Central IRB** for review and oversight of small and large clinical trials and research studies to advance acute stroke treatment, stroke prevention, and recovery and rehabilitation following a stroke.  
   3. **Independent IRBs** for review and oversight of Phase 2B and above industry-authored clinical trials, including:  
      a) Western IRB (WIRB) or its affiliates,  
      b) Advarra (formerly Schulman Associates and Chesapeake IRB), or  
      c) Quorum Review.

G. UCI continues to enter into IRB Authorization Agreements and MOUs to support single IRB review of multi-site trials and cooperative research.
VII. Transferring IRB Oversight / Continuity
A. To prevent lapses in human subject protection, it is generally preferred that the same IRB retain oversight responsibility throughout the conduct of a study, if possible. That said, sometimes transfers to another IRB for subsequent review and oversight is desired or necessary (e.g., sponsor request, workload redistribution – temporary or permanent, unexpected, adverse events such as natural disaster).

B. When transferring IRB oversight, the original IRB works closely with the clinical investigator, the receiving IRB, and the sponsor, as appropriate, throughout the transfer process to assure continuous IRB oversight with no lapse in either IRB approval or the protection of human subjects, and with minimal disruption of research activities.

C. The breadth and duration of the IRB transfer process may vary depending on the reason for the transfer, the entities involved, and the number and type of studies being transferred.

D. When transferring ongoing research to another IRB, UCI will assure that the terms and responsibilities of the Reviewing IRB and UCI as the ceding institution are documented in an IRB Master Agreement.

E. In general, the IRB transfer process involves:
   1. Identifying the studies to be transferred;
   2. Ensuring the availability and retention of pertinent research records;
   3. Establishing an effective date for transfer of oversight, including IRB records, for the clinical investigation(s) and other types of studies;
   4. Receiving IRB conducts a review of the studies (new or continuing review), as appropriate, before it accepts responsibility for the studies;
   5. Confirming or establishing the date for the next continuing review;
   6. Determining whether the consent form needs to be revised;
   7. Notifying the Original IRB, the investigator, and sponsor; and
   8. Updating IRB registration information, as applicable.

References:
45 CFR 46
21 CFR 50 and 56, 312, 812
45 CFR 160 and 164
California Health and Safety Code Sections 24170-24179.5
Declaration of Helsinki
University Policy on Protection of Human Subjects in Research (issued September 2, 1981)
UCI Office of Research Continuity Plan – March 2014
UCI Research Policy for the Protections of Human Subjects in Research
The Belmont Report
Procedure Number: 1.A
Title: Procedure for Institutional Oversight of Assurance

Procedure:
This procedure outlines the UCI Institutional Review Board responsibilities in maintaining the UCI Federalwide Assurance.

I. Lead Researcher (LR) Responsibilities
A. Obtains the appropriate knowledge regarding human subjects protections, ethics, federal regulations, training, and monitoring to conduct his/her proposed research.
B. Assures that the research team is adequately trained and knowledgeable regarding human subjects protections, ethical considerations, and Federal regulations applicable to the proposed research.
C. Complies with the training, monitoring, and human research guidance as outlined in the Assurance and IRB policies and procedures.
D. Assures that when UCI is ceding IRB review, the study or clinical trial is registered with UCI IRB.
E. Complies with the determinations and requirements of the IRB of record and follows the policies of the IRB of record.
F. Reports Unanticipated Problems involving Risks to Subjects or Others, and potential Serious Noncompliance or Continuing Noncompliance instances to the IRB of record and to UCI IRB when UCI is ceding review.

II. Institutional Official (IO) Responsibilities
A. Allocates the Office of Research budget
B. Ensure that the Human Research Protections unit and the IRB has sufficient resources, including IRBs appropriate for the volume and types of human research to be reviewed, so that reviews are accomplished in a thorough and timely manner.
C. Speak for and legally commit the institution to adherence to the requirements of the federal regulations regarding the involvement of human subjects in biomedical and social-behavioral research.
D. Assures institutional compliance with the Assurance, federal regulations, state statutes, and UC/UCI policies and procedures.
E. Appoints and removes members for service on the UCI IRBs.
F. Review and sign federal assurances and addenda.
G. Ensures ongoing authority and autonomy of the IRBs to perform their function.
H. Provides adequate resources for maintenance of human subject protection at UCI, including HRP staff, facilities, resources and equipment.
I. Reports to the Executive Vice Chancellor, communicates with the Vice Chancellor, Health Affairs, Vice Chancellor Health Affairs, the Deans of the Schools and other campus officials regarding human subjects protection issues.
J. Suspends or terminates IRB approval of research.
K. Disapproves research approved by the IRB.
III. **Associate Vice Chancellor for Research Administration (AVCRA) for Research Responsibilities**
   A. Oversees and manages the activities of the OR to promote responsible and ethical conduct in research and to ensure cooperation among individuals and offices that support research and other sponsored activities.
   B. Creates the Human Research Protection Program budget
   C. Reviews and authorizes sIRB MOUs.

IV. **IRB Committee Responsibilities**
   A. Reviews all human subjects research activities and document its findings regarding ethical considerations, scientific merit in regard to the risk/benefit profile, adherence to federal regulations, state statutes, and IRB policies and procedures.
   B. Reviews and monitors ongoing research for adherence to the federal regulations, state statutes, and IRB policies and procedures.
   C. Has the authority to suspend or terminate approval of research that is not being conducted in accordance with the IRB's requirements or that has been associated with unexpected serious harm to subjects. The IRB's action of suspension or termination shall be reported promptly to the investigators, appropriate institutional officers, and the Secretary of HHS.
   D. When UCI is ceding IRB review, the IRB subcommittee may confirm the appropriateness of ceding research that involves greater than minimal risk.

V. **Executive Director of Research Protections Responsibilities**
   A. Assures that UCI's Federalwide Assurance and IRB registration is updated or renewed at least every three years.
   B. Ensures that amendments to the Assurance are reported promptly to OHRP, as required. Amendments are submitted to OHRP by the RP Executive Director or designee.
   C. Assures that UCI maintains standard policies and procedures (SOPPs) reflecting the current practices of the IRB in conducting reviews and approvals under its Assurance.
      1. These policies and procedures will be maintained and kept current by UCI's Human Research Protections staff. The SOPPs will be re-reviewed at least every three years. All revision dates will be listed under the revision date section for each policy and procedure.
      2. Changes in policy are to be determined by the IRB Chairs, the Associate Vice Chancellor for Research, and the Human Research Protections Management. As appropriate, procedures are developed and revised by the Research Protections’ Executive Director or designee.
      3. All procedures are to be approved by the Executive Director of Research Protections.
   D. Oversees program implementation and management and communicates to the IO or his/her designee any human research protections issues that are likely to present risks or other concerns to the institution.
   E. Coordinates, on behalf of the IRB, prompt reporting to the IO and to governmental oversight entities of unanticipated problems involving risks to subjects or others, serious or continuing non-compliance with Federal regulations or IRB requirements, and suspension or termination of IRB approval.
   F. Maintains, as the official institutional record, all documents pertaining to UCI's Assurance and compliance activity.
   G. Overall responsibility for management and supervision of all HRP personnel.
   H. Reviews and negotiates sIRB agreements (IAAs and MOUs). The Executive Director or designee has the authority to sign IAAs (single protocol agreements).
VI. Annually, the budget for the IRB and the HRP will be reviewed by the Vice Chancellor for Research, the Associate Vice Chancellor for Research and the Executive Director of Research Protections and modified as necessary to accommodate the volume and type of research reviewed, space, facilities and staff.